Cencora, Inc. (COR) Earnings Call Transcripts

Cencora, Inc.'s Latest Earnings Call - September 8, 2026

Cencora, Inc. reported strong performance in Q3 of fiscal 2026, with management highlighting continued growth in specialty pharmaceuticals and a strategic share repurchase of $1 billion. Revenue guidance for Q4 remains robust, reflecting a strong underlying utilization trend despite some volume loss from Walgreens. The company anticipates a strong finish to the fiscal year, maintaining its outlook for growth driven by specialty areas and international business performance.

Reported metrics

Guidance from management

Cencora maintains a strong outlook for Q4, expecting continued growth driven by specialty pharmaceuticals and international business performance. Guidance remains unchanged, reflecting confidence in underlying utilization trends.

What management said

Yes. I think, Bob, the only thing I would add is we wanted to provide to the investor community the full factual context around that and a couple of things. One, the business began moving in July. So at the start of the fiscal fourth quarter, to -- it was contemplated in our guidance, which shows the acceleration in Q4, the guidance we provided back in August. And finally, three, as Bob said, the vast majority of our...

Yes. I appreciate the question, and we'll have a fulsome update of 2027 on our Q4 earnings call. We're in the throes we're in the heart of our planning process. In terms of -- you called out MWI and what we said to investors was assume a mid-year transaction. We have no updates on the exact timing but felt that was a balanced assumption to take. I would remind investors that will benefit from the continued annualizat...

What analysts pressed on

Analysts expressed concerns about the impact of Walgreens volume loss on overall revenue and the potential for volatility in organic growth rates. There is also apprehension regarding the long-term implications of the IRA on reimbursement for Part B drugs.

Main topics on the call

• Revenue Guidance for Q4 — Management provided a strong revenue guidance for Q4, indicating an acceleration from Q3. CEO Bob Mauch stated, "We expect strong year in line with our guidance," reflecting confidence in underlying utilization trends, p...
• Impact of Walgreens Volume Loss — The company acknowledged a loss of certain volumes from Walgreens that are outside the prime vendor agreement. CFO Eva Boratto noted, "the vast majority of our business with Walgreens is in the prime contract, not outsid...
• Performance of 1 Oncology Acquisition — Management reported that the 1 Oncology acquisition is performing slightly better than expected, with opportunities for growth in clinical research and revenue cycle management. Boratto mentioned, "We continue to expect ...
• International Business Recovery — Cencora's international business is showing improved performance, driven by the World Courier and 3PL segments. Boratto stated, "We see consistent demand," indicating a positive outlook for international operations.

Read the full Cencora, Inc. transcript (September 8, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 76 Cencora, Inc. earnings call transcripts on record, spanning January 9, 2020 to September 8, 2026. Based on this history, Cencora, Inc. reports quarterly. The most recent call on file is dated September 8, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

COR

Exchange

NYSE

Country

US

Sector

Health Care

Industry

Health Care Providers and Services

Calls on record

76

First call

January 9, 2020

Most recent

September 8, 2026

Reporting cadence

quarterly